Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provisionHannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Gerd-Marie Alenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad-d'Elia, Alf Kastbom, Lars Klareskog, Elisabet Lindqvist, Ulf Lindström, Carl Turesson, Christopher SjöwallSee the full list of authors
8 December 2021
Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodiesChiara Tani, Federico Pratesi, Rosaria Talarico, Chiara Cardelli, Teresita Caruso, Federica Di Cianni, Elenia Laurino, Nazzareno Italiano, Michele Moretti, Maria Laura Manca, Paola Migliorini, Marta Mosca
8 December 2021
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapiesUlf M Geisen, Melike Sümbül, Florian Tran, Dennis K Berner, Hayley M Reid, Lena Vullriede, Maria Ciripoi, Ann C Longardt, Paula Hoff, Peter J Morrison, Verena E Schneider, Rainald Zeuner, Jan H Schirmer, Andrea Steinbach, Susanna NikolausSee the full list of authors
8 December 2021
Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case seriesTheerada Assawasaksakul, Seelwan Sathitratanacheewin, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Yong Poovorawan, Wonngarm Kittanamongkolchai
3 December 2021
Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximabCathy Mireille Melong Pianta Taleng, Kim Lauper, Benoit Gilbert, Tim Cunningham, Romain Guemara, Laure Brulhart, Diana Dan, Delphine Courvoisier, Axel Finckh
3 December 2021
Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC studyMarlou THF Janssen, Sofia Ramiro, Rémy LM Mostard, Cesar Magro-Checa, Robert BM Landewé
24 November 2021
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMDAnne Constanze Regierer, Rebecca Hasseli, Martin Schäfer, Bimba F Hoyer, Andreas Krause, Hanns-Martin Lorenz, Alexander Pfeil, Jutta Richter, Tim Schmeiser, Hendrik Schulze-Koops, Anja Strangfeld, Reinhard E Voll, Christof Specker, Ulf Mueller-Ladner
20 October 2021
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine SurveySebastian Eduardo Sattui, Jean W Liew, Kevin Kennedy, Emily Sirotich, Michael Putman, Tarin T Moni, Akpabio Akpabio, Deshiré Alpízar-Rodríguez, Francis Berenbaum, Inita Bulina, Richard Conway, Aman Dev Singh, Eimear Duff, Karen L Durrant, Tamer A GheitaSee the full list of authors
7 September 2021
Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based surveyFrancesco Ursini, Jacopo Ciaffi, Luana Mancarella, Lucia Lisi, Veronica Brusi, Carlotta Cavallari, Martina D’Onghia, Anna Mari, Elena Borlandelli, Jacopo Faranda Cordella, Micaela La Regina, Pasquale Viola, Piero Ruscitti, Marco Miceli, Roberto De GiorgioSee the full list of authors
23 August 2021
Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in GermanyClaudia Sengler, Sascha Eulert, Kirsten Minden, Martina Niewerth, Gerd Horneff, Jasmin Kuemmerle-Deschner, Caroline Siemer, Rainer Berendes, Hermann Girschick, Regina Hühn, Michael Borte, Anton Hospach, Wolfgang Emminger, Jakob Armann, Ariane KleinSee the full list of authors
26 July 2021
